CDC42 and central nervous system cancer: Our study found that several immune checkpoints (BTLA, CD200R1, PD-L1, B7-H3, CD70, CTLA4, IDO1, and PD1) in patients with CDC42 high expression glioma were upregulated compared to the CDC42 low expression group.